Effects of ABT-089 on Smoking Abstinence Symptoms and Reward
Status:
Terminated
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
This Phase IIa within-subject, cross-over pilot study will evaluate the effects of ABT-089
(an experimental medication not approved by the FDA) when administered as 40mg oral once
daily dose for 10 days, compared to placebo, on the following: abstinence-induced cognitive
deficits, smoking withdrawal, smoking urges, smoking reward, and a brief, monitored quit
attempt (~4 days). The key cognitive domains include: working memory, sustained attention,
and response inhibition.